7 results on '"Halabi, Susan"'
Search Results
2. In-depth Analysis of the 2019 Advanced Prostate Cancer Consensus Conference: The Importance of Representation of Medical Specialty and Geographic Regions
- Author
-
Pratsinis, Manolis, Halabi, Susan, Güsewell, Sabine, Gillessen, Silke, and Omlin, Aurelius
- Published
- 2021
- Full Text
- View/download PDF
3. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]
- Author
-
Gillessen, Silke, Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Bossi, Alberto, Briganti, Alberto, Bristow, Rob G., Chi, Kim N., Clarke, Noel, Davis, Ian D., de Bono, Johann, Drake, Charles G., Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fizazi, Karim, Frydenberg, Mark, Gleave, Martin, Halabi, Susan, Heidenreich, Axel, Heinrich, Daniel, Higano, Celestia (Tia) S., Hofman, Michael S., Hussain, Maha, James, Nicolas, Kanesvaran, Ravindran, Kantoff, Philip, Khauli, Raja B., Leibowitz, Raya, Logothetis, Chris, Maluf, Fernando, Millman, Robin, Morgans, Alicia K., Morris, Michael J., Mottet, Nicolas, Mrabti, Hind, Murphy, Declan G., Murthy, Vedang, Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Parker, Chris, Poon, Darren M.C., Pritchard, Colin C., Reiter, Robert E., Roach, Mack, Rubin, Mark, Ryan, Charles J., Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I., Shore, Neal, Small, Eric, Smith, Matthew, Soule, Howard, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew R., Taplin, Mary Ellen, Tombal, Bertrand, Türkeri, Levent, van Oort, Inge, Zapatero, Almudena, Omlin, Aurelius, Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Chi, K. N., Clarke, N., Davis, I. D., de Bono, J., Drake, C. G., Duran, I., Eeles, R., Efstathiou, E., Evans, C. P., Fanti, S., Feng, F. Y., Fizazi, K., Frydenberg, M., Gleave, M., Halabi, S., Heidenreich, A., Heinrich, D., Higano, C. T. S., Hofman, M. S., Hussain, M., James, N., Kanesvaran, R., Kantoff, P., Khauli, R. B., Leibowitz, R., Logothetis, C., Maluf, F., Millman, R., Morgans, A. K., Morris, M. J., Mottet, N., Mrabti, H., Murphy, D. G., Murthy, V., Oh, W. K., Ost, P., O'Sullivan, J. M., Padhani, A. R., Parker, C., Poon, D. M. C., Pritchard, C. C., Reiter, R. E., Roach, M., Rubin, M., Ryan, C. J., Saad, F., Sade, J. P., Sartor, O., Scher, H. I., Shore, N., Small, E., Smith, M., Soule, H., Sternberg, C. N., Steuber, T., Suzuki, H., Sweeney, C., Sydes, M. R., Taplin, M. -E., Tombal, B., Turkeri, L., van Oort, I., Zapatero, A., and Omlin, A.
- Subjects
Tumour genomic profiling ,Manchester Cancer Research Centre ,Advanced prostate cancer ,ResearchInstitutes_Networks_Beacons/mcrc ,Progression-free survival ,Hormone-sensitive prostate cancer ,Oligometastatic prostate cancer ,Imaging ,High-risk localised prostate cancer ,Prostate cancer treatment ,Castration-naïve prostate cancer ,Genetics ,Overall survival ,Castration-resistant prostate cancer - Abstract
Background: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some of these topics to supplement guidelines that are based on level 1 evidence. Objective: To present the results from the APCCC 2019. Design, setting, and participants: Similar to prior conferences, experts identified 10 important areas of controversy regarding the management of advanced prostate cancer: locally advanced disease, biochemical recurrence after local therapy, treating the primary tumour in the metastatic setting, metastatic hormone-sensitive/naïve prostate cancer, nonmetastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, bone health and bone metastases, molecular characterisation of tissue and blood, inter- and intrapatient heterogeneity, and adverse effects of hormonal therapy and their management. A panel of 72 international prostate cancer experts developed the programme and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 123 predefined questions, which were developed by both voting and nonvoting panel members prior to the conference following a modified Delphi process. Results and limitations: Panellists voted based on their opinions rather than a standard literature review or formal meta-analysis. The answer options for the consensus questions had varying degrees of support by the panel, as reflected in this article and the detailed voting results reported in the Supplementary material. Conclusions: These voting results from a panel of prostate cancer experts can help clinicians and patients navigate controversial areas of advanced prostate management for which high-level evidence is sparse. However, diagnostic and treatment decisions should always be individualised based on patient-specific factors, such as disease extent and location, prior lines of therapy, comorbidities, and treatment preferences, together with current and emerging clinical evidence and logistic and economic constraints. Clinical trial enrolment for men with advanced prostate cancer should be strongly encouraged. Importantly, APCCC 2019 once again identified important questions that merit assessment in specifically designed trials. Patient summary: The Advanced Prostate Cancer Consensus Conference provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference, which has been held three times since 2015, aims to share the knowledge of world experts in prostate cancer management with health care providers worldwide. At the end of the conference, an expert panel discusses and votes on predefined consensus questions that target the most clinically relevant areas of advanced prostate cancer treatment. The results of the voting provide a practical guide to help clinicians discuss therapeutic options with patients as part of shared and multidisciplinary decision making.
- Published
- 2020
4. Best (but oft-forgotten) practices: sample size and power calculation for a dietary intervention trial with episodically consumed foods.
- Author
-
Zhang, Wei, Liu, Aiyi, Zhang, Zhiwei, Nansel, Tonja, and Halabi, Susan
- Subjects
EXPERIMENTAL design ,INGESTION ,MEDICAL research ,STATISTICAL hypothesis testing ,STATISTICS ,SAMPLE size (Statistics) ,STATISTICAL power analysis ,DATA analysis - Abstract
Dietary interventions often target foods that are underconsumed relative to dietary guidelines, such as vegetables, fruits, and whole grains. Because these foods are only consumed episodically for some participants, data from such a study often contains a disproportionally large number of zeros due to study participants who do not consume any of the target foods on the days that dietary intake is assessed, thus generating semicontinuous data. These zeros need to be properly accounted for when calculating sample sizes to ensure that the study is adequately powered to detect a meaningful intervention effect size. Nonetheless, this issue has not been well addressed in the literature. Instead, methods that are common for continuous outcomes are typically used to compute the sample sizes, resulting in a substantially under- or overpowered study. We propose proper approaches to calculating the sample size needed for dietary intervention studies that target episodically consumed foods. Sample size formulae are derived for detecting the mean difference in the amount of intake of an episodically consumed food between an intervention and a control group. Numerical studies are conducted to investigate the accuracy of the sample size formulae as compared with the ad hoc methods. The simulation results show that the proposed formulae are appropriate for estimating the sample sizes needed to achieve the desired power for the study. The proposed method for sample size is recommended for designing dietary intervention studies targeting episodically consumed foods. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools.
- Author
-
Mahar, Alyson L., Compton, Carolyn, McShane, Lisa M., Halabi, Susan, Asamura, Hisao, Rami-Porta, Ramon, Groome, Patti A., Molecular Modellers Working Group of the American Joint Committee on Cancer, and Molecular Modellers Working Group of American Joint Committee on Cancer
- Published
- 2015
- Full Text
- View/download PDF
6. Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study
- Author
-
Rini, Brian I., Halabi, Susan, Barrier, Robert, Margolin, Kim A., Avigan, David, Logan, Theodore, Stadler, Walter M., McCarthy, Philip L., Linker, Charles A., and Small, Eric J.
- Subjects
- *
CANCER patients , *GRAFT versus host disease , *CELLULAR therapy , *STEM cells - Abstract
Abstract: A graft-versus-tumor effect through nonmyeloablative allogeneic stem cell transplantation (N-SCT) in metastatic renal cell carcinoma (RCC) has been reported. An Intergroup phase II trial was undertaken to define further the feasibility, toxicity and efficacy of this approach in a multi-institutional setting, Patients with cytokine-refractory, metastatic RCC were treated with N-SCT. The conditioning regimen was fludarabine 30 mg·m−2 ·d−1 on day (d) −7 through d −3 and cyclophosphamide 60 mg·kg−1 ·d−1 on d −4 and d −3. Patients received 2-8 × 106 CD34+ cells/kg of granulocyte colony-stimulating factor mobilized stem cells from a 6/6 HLA-matched sibling donor. Immunosuppression after transplantation included tacrolimus and methotrexate. Twenty-two patients were enrolled at 14 institutions. Greater than 90% donor T-cell chimerism was observed in 17 of 19 evaluable patients (89%) by d +120. No objective response was observed. Acute graft-versus-host disease (GVHD) was observed in 11 patients (50%). Chronic GVHD was reported in 5 patients (23%). There was 1 patient death from liver failure secondary to chronic GVHD. Regimen-related mortality was 2 of 22 (9%; liver failure, sepsis). Median survival time was 5.5 months (95% confidence interval, 3.9-12.0 months) and the median time to progression was 3.0 months (95% confidence interval, 2.3-4.2 months). N-SCT for metastatic RCC is feasible in a multi-institutional setting. Adequate donor T-cell engraftment was achieved in most patients before disease progression. A graft-versus-tumor effect was not observed in this study despite acute and chronic GVHD, thus highlighting the need for further understanding of this approach. Allogeneic SCT remains investigational in RCC. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
7. Estimating historical atmospheric mercury concentrations from silver mining and their legacies in present-day surface soil in Potosí, Bolivia
- Author
-
Hagan, Nicole, Robins, Nicholas, Hsu-Kim, Heileen, Halabi, Susan, Morris, Mark, Woodall, George, Zhang, Tong, Bacon, Allan, Richter, Daniel de B., and Vandenberg, John
- Subjects
- *
ATMOSPHERIC mercury , *SILVER mining , *EMISSIONS (Air pollution) , *MERCURY vapor , *RESPIRATORY therapy , *OCCUPATIONAL diseases - Abstract
Abstract: Detailed Spanish records of mercury use and silver production during the colonial period in Potosí, Bolivia were evaluated to estimate atmospheric emissions of mercury from silver smelting. Mercury was used in the silver production process in Potosí and nearly 32,000 metric tons of mercury were released to the environment. AERMOD was used in combination with the estimated emissions to approximate historical air concentrations of mercury from colonial mining operations during 1715, a year of relatively low silver production. Source characteristics were selected from archival documents, colonial maps and images of silver smelters in Potosí and a base case of input parameters was selected. Input parameters were varied to understand the sensitivity of the model to each parameter. Modeled maximum 1-h concentrations were most sensitive to stack height and diameter, whereas an index of community exposure was relatively insensitive to uncertainty in input parameters. Modeled 1-h and long-term concentrations were compared to inhalation reference values for elemental mercury vapor. Estimated 1-h maximum concentrations within 500 m of the silver smelters consistently exceeded present-day occupational inhalation reference values. Additionally, the entire community was estimated to have been exposed to levels of mercury vapor that exceed present-day acute inhalation reference values for the general public. Estimated long-term maximum concentrations of mercury were predicted to substantially exceed the EPA Reference Concentration for areas within 600 m of the silver smelters. A concentration gradient predicted by AERMOD was used to select soil sampling locations along transects in Potosí. Total mercury in soils ranged from 0.105 to 155 mg kg−1, among the highest levels reported for surface soils in the scientific literature. The correlation between estimated air concentrations and measured soil concentrations will guide future research to determine the extent to which the current community of Potosí and vicinity is at risk of adverse health effects from historical mercury contamination. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.